Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016

  • ID: 3802770
  • Drug Pipelines
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Genentech, Inc.
  • Nimbus Therapeutics, LLC
  • Sareum Holdings Plc
  • MORE
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016

Summary

‘Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016’, provides in depth analysis on Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2)
- The report reviews Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Genentech, Inc.
  • Nimbus Therapeutics, LLC
  • Sareum Holdings Plc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Overview

Therapeutics Development

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Stage of Development

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Therapy Area

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Indication

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Companies

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Universities/Institutes

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Array BioPharma Inc.

Bristol-Myers Squibb Company

Genentech, Inc.

Nimbus Therapeutics, LLC

Portola Pharmaceuticals, Inc.

Sareum Holdings Plc

Takeda Pharmaceutical Company Limited

Theravance Biopharma, Inc.

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Drug Profiles

ARRY-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-33 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TYK2 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TYK2 for Psoriasis and IBD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tyk2 for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Discontinued Products

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Featured News & Press Releases

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings

Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016

Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor

Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor

Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition

Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs

Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor

Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK

May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib

May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting

Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme

Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting

Oct 01, 2014: Sareum Holdings Promising Step in Psoriasis Drug Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 62List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Array BioPharma Inc., H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Genentech, Inc., H1 2016

Pipeline by Nimbus Therapeutics, LLC, H1 2016

Pipeline by Portola Pharmaceuticals, Inc., H1 2016

Pipeline by Sareum Holdings Plc, H1 2016

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Pipeline by Theravance Biopharma, Inc., H1 2016

Discontinued Products, H1 2016 47List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Genentech, Inc.
  • Nimbus Therapeutics, LLC
  • Sareum Holdings Plc
  • MORE
According to the author's, recently published report 'Non-Receptor Tyrosine-Protein Kinase TYK2 - Pipeline Review, H1 2016'; Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the author says; Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.

The report 'Non-Receptor Tyrosine-Protein Kinase TYK2 - Pipeline Review, H1 2016' outlays comprehensive information on the Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 5
Array BioPharma Inc.
Bristol-Myers Squibb Company
Genentech, Inc.
Nimbus Therapeutics, LLC
Portola Pharmaceuticals, Inc.
Sareum Holdings Plc
Takeda Pharmaceutical Company Limited
Theravance Biopharma, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll